Article Versions Notes

Wotring JW, McCarty SM, Shafiq K, Zhang CJ, Nguyen T, Meyer SR, Fursmidt R, Mirabelli C, Clasby MC, Wobus CE, et al. In Vitro Evaluation and Mitigation of Niclosamide’s Liabilities as a COVID-19 Treatment. Vaccines. 2022; 10(8):1284. https://doi.org/10.3390/vaccines10081284

Wotring, Jesse W., Sean M. McCarty, Khadija Shafiq, Charles J. Zhang, Theophilus Nguyen, Sophia R. Meyer, Reid Fursmidt, Carmen Mirabelli, Martin C. Clasby, Christiane E. Wobus, and et al. 2022. "In Vitro Evaluation and Mitigation of Niclosamide’s Liabilities as a COVID-19 Treatment" Vaccines 10, no. 8: 1284. https://doi.org/10.3390/vaccines10081284

Wotring, J. W., McCarty, S. M., Shafiq, K., Zhang, C. J., Nguyen, T., Meyer, S. R., Fursmidt, R., Mirabelli, C., Clasby, M. C., Wobus, C. E., O’Meara, M. J., & Sexton, J. Z. (2022). In Vitro Evaluation and Mitigation of Niclosamide’s Liabilities as a COVID-19 Treatment. Vaccines, 10(8), 1284. https://doi.org/10.3390/vaccines10081284